Skip to main content

Advertisement

SpringerLink
Log in

Impact of CD123 expression, analyzed by immunohistochemistry, on clinical outcomes in patients with acute myeloid leukemia

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Aberrant expression of the interleukin-3 receptor alpha chain (IL3RA or CD123) is frequently observed in patients with a subset of leukemic disorders, including acute myeloid leukemia (AML), particularly in leukemia stem cells. We analyzed the relationships between immunohistochemical (IHC) expression, including that of CD123, and clinical outcomes. This study involved a retrospective analysis of 48 patients diagnosed with de novo AML (M0–M5, n = 48) at our hospital between February 2008 and September 2015. Among patients with de novo AML, CD123 expression was associated with a failure to achieve complete response (CR) to initial induction chemotherapy (P = 0.044) and poor overall survival (OS) (P = 0.036). This is the first study using IHC to demonstrate that CD123 expression is associated with a poor CR rate and poor OS in de novo AML patients. These results support previous reports using flow cytometry (FCM). CD123 expression may thus be useful for assessing AML patients’ prognoses. At the time of diagnosis, CD123 expression analysis using IHC may represent a clinically useful assessment for de novo AML patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Testa U, Riccioni R, Diverio D, Rossini A, Lo Coco F, Peschle C. Interleukin-3 receptor in acute leukemia. Leukemia. 2004;18:219–26.

    Article  CAS  PubMed  Google Scholar 

  2. Testa U, Pelosi E, Frankel A. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomark Res. 2014;2:4.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Muñoz L, Nomdedéu JF, López O, Carnicer MJ, Bellido M, Aventín A, et al. Interleukin-3 receptor α chain (CD123) is widely expressed in hematologic malignancies. Haematologica. 2001;86:1261–9.

    PubMed  Google Scholar 

  4. Ihle JN. Interleukin-3 and hematopoiesis. Chem Immunol. 1992;51:65–106.

    CAS  PubMed  Google Scholar 

  5. Blalock WL, Weinstein-Oppenheimer C, Chang F, Hoyle PE, Wang XY, Algate PA, et al. Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs. Leukemia Aug. 1999;13:1109–66.

    Article  CAS  Google Scholar 

  6. Testa U, Riccioni R, Militi S, Coccia E, Stellacci E, Samoggia P, et al. Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood. 2002;100:2980–8.

    Article  CAS  PubMed  Google Scholar 

  7. Rollins-Raval M, Pillai R, Warita K, Mitsuhashi-Warita T, Mehta R, Boyiadzis M, et al. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations. Appl Immunohistochem Mol Morphol. 2003;21:212–7.

    Google Scholar 

  8. Fernandez-Pol S, Ma L, Ohgami RS, Arber DA. Immunohistochemistry for p53 is a useful tool to identify cases of acute myeloid leukemia with myelodysplasia-related changes that are TP53 mutated, have complex karyotype, and have poor prognosis. Mod Pathol. 2017;30:382–92.

    Article  CAS  PubMed  Google Scholar 

  9. Hou HA, Chou WC, Kuo YY, Liu CY, Lin LI, Tseng MH, et al. TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution. Blood Cancer J. 2015;5:e331.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Orazi A, Cattoretti G, Heerema NA, Sozzi G, John K, Neiman RS. Frequent p53 overexpression in therapy related myelodysplastic syndromes and acute myeloid leukemias: an immunohistochemical study of bone marrow biopsies. Mod Pathol. 1993;6:521–5.

    CAS  PubMed  Google Scholar 

  11. McGraw KL, Nguyen J, Komrokji RS, Sallman D, Al Ali NH, Padron E, et al. Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia. Haematologica. 2016;101:e320.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Vergez F, Green AS, Tamburini J, Sarry JE, Gaillard B, Cornillet-Lefebvre P, et al. High levels of CD34 + CD38 low/-CD123 + blasts are predictive of an adverse outcome in acute myeloid leukemia: a groupeouest-est des leucémiesaiguës et maladies du sang (GOELAMS) study. Haematologica. 2011;96:1792–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Robert CB Jr, Daniel PR, Susan FH, Herbert B, John F Jr MJ, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19(6):1865–78.

    Article  Google Scholar 

  14. Hattori N, Fukuchi K, Nakamaki T, Homma M, Ariizumi H, Nakashima H, et al. P53 protein expression in chronic myelomonocytic leukemia-1 correlates with progression to leukemia and a poor prognosis. Acta Haematol. 2011;125:242–6.

    Article  PubMed  Google Scholar 

  15. Iwasaki T, Murakami M, Sugisaki C, Sobue S, Ohashi H, Asano H, et al. Characterization of myelodysplastic syndrome and aplastic anemia by immunostaining of p53 and hemoglobin F and karyotype analysis: differential diagnosis between refractory anemia and aplastic anemia. Pathol Int. 2008;58:353–60.

    Article  PubMed  Google Scholar 

  16. Al-Mawali A, Gillis D, Lewis I. Immunoprofiling of leukemic stem cells CD34+/CD38–/CD123 + delineate FLT3/ITD-positive clones. J Hematol Oncol. 2016;9:61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Ehninger A, Kramer M, Röllig C, Thiede C, Bornhäuser M, von Bonin M,et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J. 2014;4:e218.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453–74.

    Article  CAS  PubMed  Google Scholar 

  19. Stein C, Kellner C, Kügler M, Reiff N, Mentz K, Schwenkert M, et al. Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells: research paper. Br J Haematol. 2010;148:879–89.

    Article  CAS  PubMed  Google Scholar 

  20. Majeti R. Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. Oncogene. 2011;30:1009–19.

    Article  CAS  PubMed  Google Scholar 

  21. Hanekamp D, Closs J, Schuurhuis GJ. Leukemia stem cells; identification and clinical application. Int J Hematol. 2017;105:549–57.

    Article  CAS  PubMed  Google Scholar 

  22. Al-Hussaini M, Rettig MP, Ritchey JK, Karpova D, Uy GL, Eissenberg LG, et al. Targeting CD123 in acute myeloid leukemia using a T-cell—directed dual-affinity retargeting platform. Blood. 2016;127:122–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Li G, Li X, Wu H, Yang X, Zhang Y, Chen L, et al. CD123 targeting oncolytic adenoviruses suppress acute myeloid leukemia cell proliferation in vitro and in vivo. Blood Cancer J. 2014;4:194.

    Article  Google Scholar 

  24. Tettamanti S, Marin V, Pizzitola I, Magnani CF, Giordano Attianese GM, et al. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br J Haematol. 2013;161:389–401.

    Article  CAS  PubMed  Google Scholar 

  25. Pizzitola I, Anjos-Afonso F, Rouault-Pierre K, Lassailly F, Tettamanti S, Spinelli O, et al. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia. 2014;28:1596–605.

    Article  CAS  PubMed  Google Scholar 

  26. Moradi-Kalbolandi S, Habibi-Anbouhi M, Golkar M, Behdani M, Rezaei G, Ghazizadeh L, et al. Development of a novel engineered antibody targeting human CD123. Anal Biochem. 2016;511:27–30.

    Article  CAS  PubMed  Google Scholar 

  27. Mardiros A, Dos Santos C, McDonald T, Brown CE, Wang X, Budde LE, et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood. 2013;122:3138–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Jin L, Lee EM, Ramshaw HS, Busfield SJ, Peoppl AG, Wilkinson L, et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell. 2009;1:31–42.

    Article  CAS  Google Scholar 

  29. Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014;124:385–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We wish to thank all physicians, nurses, pharmacists, and support personnel for their care of patients in this study.

Author information

Authors and Affiliations

  1. Department of Pathology, Showa University School of Medicine, Tokyo, Japan

    Nana Arai, Mayumi Homma, Eisuke Shiozawa, Toshiko Yamochi-Onizuka & Masafumi Takimoto

  2. Division of Hematology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-Ku, Tokyo, 142-8666, Japan

    Nana Arai, Maasa Abe, Yuta Baba, So Murai, Megumi Watanuki, Yukiko Kawaguchi, Shun Fujiwara, Nobuyuki Kabasawa, Hiroyuki Tsukamoto, Yui Uto, Hirotsugu Ariizumi, Kouji Yanagisawa, Norimichi Hattori, Bungo Saito & Tsuyoshi Nakamaki

  3. Division of Hematology, Department of Medicine, Showa University Fujigaoka Hospital, Kanagawa, Japan

    Hiroshi Harada

Authors
  1. Nana Arai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mayumi Homma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maasa Abe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yuta Baba
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. So Murai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Megumi Watanuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yukiko Kawaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shun Fujiwara
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Nobuyuki Kabasawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hiroyuki Tsukamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yui Uto
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Hirotsugu Ariizumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Kouji Yanagisawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Norimichi Hattori
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Bungo Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Eisuke Shiozawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Hiroshi Harada
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Toshiko Yamochi-Onizuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Tsuyoshi Nakamaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Masafumi Takimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nana Arai.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Arai, N., Homma, M., Abe, M. et al. Impact of CD123 expression, analyzed by immunohistochemistry, on clinical outcomes in patients with acute myeloid leukemia. Int J Hematol 109, 539–544 (2019). https://doi.org/10.1007/s12185-019-02616-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-019-02616-y

Keywords

Search

Navigation